3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
5
Recruiting
4
Terminated
2
Active not recruiting
2
Unknown
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Rectal Neoplasms
1
Prostatic Neoplasms
1
Polycystic Ovary Syndrome
1
Lipodystrophy, Familial Partial
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Interventions
Trastuzumab
16
pertuzumab
14
Capecitabine
14
Docetaxel
12
pyrotinib
11
Cyclophosphamide
11
Standard of Care
10
Paclitaxel
10
Letrozole
10
trastuzumab deruxtecan
9
Radiotherapy
9
Carboplatin
9
Fulvestrant
8
Drug Therapy
8
sacituzumab govitecan
7
dalpiciclib
7
exemestane
6
eribulin
6
Tamoxifen
6
Epirubicin
6
Anastrozole
6
pembrolizumab
5
palbociclib
5
abemaciclib
5
Surveys and Questionnaires
5
Neoadjuvant Therapy
5
Aromatase Inhibitors
5
camrelizumab
4
Sentinel Lymph Node Biopsy
4
Doxorubicin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Breast Neoplasms
×
Genetic Testing
×
Clear all
NCT07558343
2026-04-30
MATADOR2
Institut Claudius Regaud
Phase NA
Not yet recruiting
120 enrolled